Biography

Dr. Hanan S. Anbar, Ph.D., earned her Ph.D. in Pharmaceutical Sciences (Pharmacology and Toxicology) from the Faculty of Pharmacy, Mansoura University, Egypt, in 2017. She is currently an an Associate Dean, Research Chair, Institutional Review Board, Associate Professor of Pharmacology and Toxicology at College of Pharmacy of Pharmacology and Toxicology at Dubai Pharmacy College for Girls, Dubai, United Arab Emirates. Dr. Anbar has authored over 44 publications in highly reputed international peer-reviewed journals. Her H-index is 16. She has presented her work at numerous international conferences. She has also served as a peer reviewer for several prestigious journals and has collaborated with prominent researchers from the USA, UK, Pakistan, UAE, Egypt, and the Republic of Korea.

Education

• Ph.D. in Pharmaceutical Sciences (Pharmacology and Toxicology), Mansoura University, Egypt, 2017

Research Interests

• Cancer
• Inflammation
• Hormonal Disturbance
• Endocrinal Disorders
• Neurodegenerative diseases

Research Publications

• Anbar, H. S., Shehab, N. G., Yasin, A., Shaar, L. M., Ashraf, R., Rahi, Z., et al. (2024). The wound healing and hypoglycemic activities of date palm (Phoenix dactylifera) leaf extract and saponins in diabetic and normal rats. PLoS One. doi:10.1371/journal.pone.0308879.
• Sebastian, A., Abu Rabah, R. R., Zaraei, S.-O., Vunnam, S., Sultan, S., Anbar, H. S., et al. (2024). Design, synthesis, biological evaluation, and in silico studies of novel pyridopyridine derivatives as anticancer candidates targeting FMS kinase. European Journal of Medicinal Chemistry, 274, 116557. doi:10.1016/j.ejmech.2024.116557.
• Hashem, O., Zaib, S., Zaraei, S.-O., Javed, H., Kedia, R. A., Anbar, H. S. (corresponding author), et al. (2024). Design and discovery of urease and Helicobacter pylori inhibitors based on benzofuran/benzothiophene-sulfonate and sulfamate scaffolds for the treatment of ureolytic bacterial infections. International Journal of Biological Macromolecules, 271, Article 132502. doi:10.1016/j.ijbiomac.2024.132502.
• Alomar, T., Baig, M. R., & Anbar, H. S. (corresponding author) (2024). Post COVID vaccination experience among the United Arab Emirates general public. Journal of Chemical Health Risks, 14(2), 319–329. doi:10.22034/jchr.2024.2006536.1948.
• Alblooshi, A. J., Baig, M. R., & Anbar, H. S. (corresponding author) (2024). Patient knowledge and pharmacists’ practice regarding the long-term side effects of proton pump inhibitors: A cross-sectional study. Archives of Academic Emergency Medicine, 12(1). doi:10.22037/aaem.v12i1.2305.
• Zaraei, S.-O., Dohle, W., Anbar, H. S., El-Gamal, R., Leblond, B., Foster, P. A., et al. (2024). Synthesis, biological evaluation, and stability studies of raloxifene mono- and bis-sulfamates as dual-targeting agents. Bioorganic & Medicinal Chemistry. doi:10.1016/j.bmc.2024.117645.
• Anbar, H. S. (corresponding author), Vahora, N. Y., Shah, H. I., Azam, M. M., Islam, T., Hersi, F., et al. (2023). Promising drug candidates for the treatment of polycystic ovary syndrome (PCOS) as alternatives to the classical medication metformin. European Journal of Pharmacology, 960, 176119. doi:10.1016/j.ejphar.2023.176119.
• El Gamal, R., Elfarrash, S., EL Nablaway, M., Salem, A. A., Zaraei, S.-O., Anbar, H. S., et al. (2023). Anti-proliferative activity of RIHMS-Qi-23 against MCF-7 breast cancer cell line is through inhibition of cell proliferation and senescence but not inhibition of targeted kinases. BMC Cancer, 23, 1053. doi:10.1186/s12885-023-11547-1.
• Shahin, A. I., Zaib, S., Zaraei, S.-O., Kedia, R. A., Anbar, H. S., Younas, M. T., et al. (2023). Design and synthesis of novel anti-urease imidazothiazole derivatives with promising antibacterial activity against Helicobacter pylori. PLoS One, 18(6), e0286684. doi:10.1371/journal.pone.0286684.
• Anbar, H. S., Shehatou, G. S. G., Abdel-Rahim, M., Suddek, G. M., & Gameil, N. M. (2023). Evaluation of regression of diabetes-induced nephropathy and vascular dysfunction in rats by montelukast via antioxidative and anti-inflammatory actions. Journal of Applied Pharmaceutical Science.
• Jairoun, S., Alkhalidi, D. K., Jairoun, A. A., & Anbar, H. S. (corresponding author) (2023). Over-the-counter antibiotic dispensing: Knowledge and practice of community pharmacists in the United Arab Emirates. Journal of Pharmaceutical Health Services Research. doi:10.1093/jphsr/rmad013.
• Siddiqui, R., Rawas-Qalaji, M., El-Gamal, M. I., Sajeev, S., Jagal, J., Zaraei, S.-O., Sbenati, M. R., Anbar S. H., et al. (2023). Novel anti-acanthamoebic activities of Irosustat and STX140 and their nanoformulations. Antibiotics, 12(3), 561. doi:10.3390/antibiotics12030561.
• Shahin, A. I., Zaraei, S.-O., Ullah, S., Anbar, H. S., El-Gamal, R., Menon, V., et al. (2023). Design and synthesis of new adamantyl derivatives as promising antiproliferative agents. European Journal of Medicinal Chemistry, 246, 114958. doi:10.1016/j.ejmech.2022.114958.
• Rafiee, M. H., Abdul Rasool, B. K., Haider, M., & Anbar, H. S. (2023). Oral pioglitazone HCl-loaded solid lipid microparticles: Formulation design and bioactivity studies. Journal of Applied Pharmaceutical Science. doi:10.7324/JAPS.2023.130218.
• Shehab, N. G., Anbar, H. S., El-Rouby, N. M. M., Abouelalamin, A., Lutfi, L., Allo, I. T., et al. (2023). New alternative herbal remedies for the treatment of letrozole-induced polycystic ovary syndrome in rats. Journal of Applied Pharmaceutical Science. doi:10.7324/JAPS.2023.130116.
• Abu Rabah, R. R., Sebastian, A., Vunnam, S., Sultan, S., Tarazi, H., Anbar, H. S., et al. (2022). Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors. Bioorganic & Medicinal Chemistry, 69, 116894. doi:10.1016/j.bmc.2022.116894.
• Zaraei, S.-O., Al-Ach, N. N., Anbar, H. S., El-Gamal, R., Tarazi, H., Tokatly, R. T., et al. (2022). Design and synthesis of new quinoline derivatives as selective C-RAF kinase inhibitors with potent anticancer activity. European Journal of Medicinal Chemistry, 238, 114434. doi:10.1016/j.ejmech.2022.114434.
• Zaib, S., Khan, I., Anbar, H. S., Zaraei, S.-O., Sbenati, R. M., Maryam, H. T., et al. (2022). Evaluation of indole-picolinamide hybrid molecules as carbonic anhydrase-II inhibitors: Biological and computational studies. Journal of Molecular Structure, 1262, 133048. doi:10.1016/j.molstruc.2022.133048.
• Anbar, H. S. (corresponding author), Shehab, N. G., El-Rouby, N. M. M., Ansari, M. A., Chenoth, H., Majeed, M., et al. (2022). Upadacitinib protects against cisplatin-induced renal and hepatic dysfunction without impairing its anticancer activity. European Journal of Pharmaceutical Sciences, 172, Article 106149. doi:10.1016/j.ejps.2022.106149.
• El-Gamal, M. I., Zaraei, S.-O., Madkour, M. M., & Anbar, H. S. (corresponding author) (2022). Evaluation of substituted pyrazole-based kinase inhibitors in one decade (2011–2020): Current status and future prospects. Molecules, 27(1), 330. doi:10.3390/molecules27010330.
• Zaib, S., Younas, M. T., Zaraei, S.-O., Khan, I., Anbar, H. S., & El-Gamal, M. I. (2022). Discovery of urease inhibitory effect of sulfamate derivatives: Biological and computational studies. Bioorganic Chemistry, 119, Article 105545. doi:10.1016/j.bioorg.2022.105545.
• El-Gamal, M. I., Mewafi, N. H., Abdelmotteleb, N. E., Emara, M. A., Tarazi, H., Sbenati, R. M., Madkour, M. M.,  Zaraei, O. S., Shahin, I. A., and Anbar H. S., (corresponding author) et al. (2021). A review of HER4 (ErbB4) kinase, its impact on cancer, and its inhibitors. Molecules, 26(23), 7376. doi:10.3390/molecules26237376.
• Zaraei, S.-O., Sbenati, R. M., Al-Ach, N. N., Anbar, H. S., El-Gamal, R., Tarazi, H., et al. (2021). Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors. European Journal of Medicinal Chemistry, 224, Article 113674. doi:10.1016/j.ejmech.2021.113674.
• Elsayed, H. R. H., Anbar, H. S., Rabei, M. R., Adel, M., & El-Gamal, R. (2021). Eicosapentaenoic and docosahexaenoic acids attenuate methotrexate-induced apoptosis and suppression of splenic T, B-lymphocytes and macrophages with modulation of expression of CD3, CD20 and CD68. Tissue and Cell, 72, Article 101533. doi:10.1016/j.tice.2021.101533.
• Ullah, S., El-Gamal, M. I., El-Gamal, R., Pelletier, J., Sévigny, J., Shehata, M. K., Anbar, H. S. (corresponding author), et al. (2021). Synthesis, biological evaluation, and docking studies of novel pyrrolo[2,3-b]pyridine derivatives as both ectonucleotide pyrophosphatase/phosphodiesterase inhibitors and antiproliferative agents. European Journal of Medicinal Chemistry, 217, Article 113339. doi:10.1016/j.ejmech.2021.113339.
• Anbar, H. S. (corresponding author), Isa, Z., Elounais, J. J., Jameel, M. A., Hussam, J., Samer, A. M., et al. (2021). Steroid sulfatase inhibitors: The current landscape. Expert Opinion on Therapeutic Patents, 31(6), 453–472. doi:10.1080/13543776.2021.1916291.
• Sbenati, R. M., Zaraei, S.-O., El-Gamal, M. I., Anbar, H. S., Tarazi, H., Zoghbor, M. M., et al. (2021). Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells. European Journal of Medicinal Chemistry, 210, Article 113081. doi:10.1016/j.ejmech.2020.113081.
• Madkour, M. M., Anbar, H. S., & El-Gamal, M. I. (2021). Current status and future prospects of p38a/MAPK14 kinase and its inhibitors. European Journal of Medicinal Chemistry, 213, Article 113216. doi:10.1016/j.ejmech.2020.113216.
• Anbar, H. S., El-Gamal, R., Ullah, S., Zaraei, S.-O., al-Rashida, M., Zaib, S., et al. (2020). Evaluation of sulfonate and sulfamate derivatives possessing benzofuran or benzothiophene nucleus as inhibitors of nucleotide pyrophosphatases/phosphodiesterases and anticancer agents. Bioorganic Chemistry, 104, Article 104305. doi:10.1016/j.bioorg.2020.104305.
• Ullah, S., El-Gamal, M. I., Zaib, S., Anbar, H. S., Zaraei, S.-O., Sbenati, R. M., et al. (2020). Synthesis, biological evaluation, and docking studies of new pyrazole-based thiourea and sulfonamide derivatives as inhibitors of nucleotide pyrophosphatase/phosphodiesterase. Bioorganic Chemistry, 99, Article 103783. doi:10.1016/j.bioorg.2020.103783.
• Anbar, H. S., El-Gamal, M. I., Tarazi, H., Lee, B. S., Jeon, H. R., Kwon, D., et al. (2020). Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: Biological and computational studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 35(1), 1712–1726. doi:10.1080/14756366.2020.1796247.
• Abduelkarem, A. R., Anbar, H. S., Zaraei, S.-O., Alfar, A. A., Al-Zoubi, O. S., Abdelkarem, E. G., & El-Gamal, M. I. (2020). Diarylamides in anticancer drug discovery: A review of pre-clinical and clinical investigations. European Journal of Medicinal Chemistry, 188, Article 112029. doi:10.1016/j.ejmech.2020.112029.
• El-Gamal, M. I., Zaraei, S.-O., Foster, P. A., Anbar, H. S., El-Gamal, R., El-Awady, R., & Potter, B. V. L. (2020). A new series of aryl sulfamate derivatives: Design, synthesis, and biological evaluation. Bioorganic & Medicinal Chemistry, 28(5), Article 115406. doi:10.1016/j.bmc.2020.115406.
• Semreen, M. H., El-Gamal, M. I., Ullah, S., Jalil, S., Zaib, S., Anbar, H. S., et al. (2019). Synthesis, biological evaluation, and molecular docking study of sulfonate derivatives as nucleotide pyrophosphatase (NPPs) inhibitors. Bioorganic & Medicinal Chemistry, 27(13), 2741–2752. doi:10.1016/j.bmc.2019.04.020.
• Zaraei, S.-O., Abduelkarem, A. R., Anbar, H. S., Kobeissi, S., Mohammad, M., Ossama, A., & El-Gamal, M. I. (2019). Sulfamates in drug design and discovery: Pre-clinical and clinical investigations. European Journal of Medicinal Chemistry, 179, 257–271. doi:10.1016/j.ejmech.2019.06.035.
• Zaraei, S.-O., El-Gamal, M. I., Shafique, Z., Amjad, S. T., Afridi, S., Zaib, S., Anbar S. H., et al. (2019). Sulfonate and sulfamate derivatives possessing benzofuran or benzothiophene nucleus as potent carbonic anhydrase II/IX/XII inhibitors. Bioorganic & Medicinal Chemistry, 27(17), 3889–3901. doi:10.1016/j.bmc.2019.07.024.
• El-Gamal, M. I., Ullah, S., Zaraei, S.-O., Jalil, S., Zaib, S., Zaher, D. M., Omar, O. H., Anbar S. H., et al. (2019). Synthesis, biological evaluation, and docking studies of new raloxifene sulfonate or sulfamate derivatives as inhibitors of nucleotide pyrophosphatase/phosphodiesterase. European Journal of Medicinal Chemistry, 181, Article 111560. doi:10.1016/j.ejmech.2019.06.034.
• El-Gamal, M. I., Anbar, H. S., Tarazi, H., & Oh, C.-H. (2019). Discovery of a potent p38a/MAPK14 kinase inhibitor: Synthesis, in vitro/in vivo biological evaluation, and docking studies. European Journal of Medicinal Chemistry, 183, Article 111684. doi:10.1016/j.ejmech.2019.111684.
• Anbar, H. S., Shehatou, G. S. G., Suddek, G. M., & Gameil, N. M. (2016). Comparison of the effect of levocetirizine and losartan on diabetic nephropathy and vascular dysfunction in streptozotocin-induced diabetic rats. European Journal of Pharmacology, 780, 82–92. doi:10.1016/j.ejphar.2016.04.012.
• El-Gamal, M. I., & Anbar, H. S. (2017). Recent advances of pyrrolopyridines derivatives: A patent and literature review. Expert Opinion on Therapeutic Patents, 27(5), 591–606. doi:10.1080/13543776.2017.1318534.
• El-Gamal, M. I., Anbar, H. S., Chung, H. J., Kim, H.-I., Cho, Y.-J., Lee, B. S., et al. (2013). Discovery of olmesartan hexetil: A new potential prodrug of olmesartan. Bioorganic & Medicinal Chemistry Letters, 23(5), 1347–1350. doi:10.1016/j.bmcl.2013.01.044.
• El-Gamal, M. I., Anbar, H. S., & Yoo, K. H. (2013). FMS kinase inhibitors: Current status and future prospects. Medicinal Research Reviews, 33(3), 599–636. doi:10.1002/med.21258.
• Chang, J.-S., El-Gamal, M. I., Lee, W. S., Anbar, H. S., Chung, H. J., Kim, H.-I., et al. (2011). Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan. European Journal of Medicinal Chemistry, 46(9), 3564–3569. doi:10.1016/j.ejmech.2011.05.054.
• Anbar, H. S., Ghoneim, H. A., El-Mowafy, A. M., & El-Kashef, H. A. (2010). Effect of COX inhibitors on renal complications of experimentally induced diabetes mellitus in rats. Mansoura Journal of Pharmaceutical Sciences, 26(1), 44–53.